ArticleDigestive diseases and sciences2000
Rebamipide, an antiulcer drug, prevents DSS-induced colitis formation in rats.
Article in Digestive diseases and sciences, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Rebampide enema therapy as a treatment for patients with chronic radiation proctitis: initial treatment or when other methods of conservative management have failed.International journal of colorectal disease · 2008Trial
- Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis.Digestive diseases and sciences · 2005Trial
- Combined Synbiotics and Omega-3 Polyunsaturated Fatty Acids Enhance Clinical and Histological Recovery in DSS-Induced Ulcerative Colitis: An Experimental Study in Rats.Diseases (Basel, Switzerland) · 2026Article
- The effects of dietary beef powder on the dextran sulfate sodium-induced colitis in a mouse model through COX-2 pathway.Food science of animal resources · 2026Article
- Innovative pH-responsive alginate-coated rosuvastatin-loaded chitosan nanoparticles: a targeted approach to inhibiting HMGB1-activated RAGE/TLR4-NFκB signaling in colonic inflammation in rats.Frontiers in pharmacology · 2025Article
- Explore Small Molecule-induced Genome-wide Transcriptional Profiles for Novel Inflammatory Bowel Disease Drug.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2016Article
- Article
- Rebamipide Promotes the Regeneration of Aspirin-Induced Small-Intestine Mucosal Injury through Accumulation of β-Catenin.PloS one · 2015Article
- Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal.Clinical ophthalmology (Auckland, N.Z.) · 2014Review
- Article
- Rebamipide suppresses diclofenac-induced intestinal permeability via mitochondrial protection in mice.World journal of gastroenterology · 2012Article
- Resolution of persistent corneal erosion after administration of topical rebamipide.Clinical ophthalmology (Auckland, N.Z.) · 2012Article
- Rebamipide promotes healing of colonic ulceration through enhanced epithelial restitution.World journal of gastroenterology · 2011Article
- Rebamipide suppresses TLR-TBK1 signaling pathway resulting in regulating IRF3/7 and IFN-α/β reduction.Journal of clinical biochemistry and nutrition · 2011Article
- Rebamipide inhibits tumor necrosis factor-α-induced interleukin-8 expression by suppressing the NF-κB signal pathway in human umbilical vein endothelial cells.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2010Article
- Novel topical therapies for distal colitis.World journal of gastrointestinal pharmacology and therapeutics · 2010Article
- Rebamipide-induced downregulation of phospholipase D inhibits inflammation and proliferation in gastric cancer cells.Experimental & molecular medicine · 2010Article
- Permeabilities of rebamipide via rat intestinal membranes and its colon specific delivery using chitosan capsule as a carrier.World journal of gastroenterology · 2008Article
- Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats.Digestive diseases and sciences · 2007Article
- Effect of rebamipide on the colonic barrier in interleukin-10-deficient mice.Digestive diseases and sciences · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was conducted to investigate the efficacy of rebamipide against experimental colitis induced by dextran sulfate sodium (DSS) in a rat model of inflammatory bowel disease. Experimental colitis was induced in male Wistar rats by oral administration of 3% DSS solution for one week. The rats were provided with standard diet containing 0.105% rebamipide (160 mg/kg/day) for 1 week. In rats treated with rebamipide, clinical (body weight loss, bloody diarrhea, reduced physical activity, severe anemia, shortened colonic length, and perianal injury) and histopathological (pathological lesion score) findings of DSS colitis were significantly less than in rats with DSS colitis not treated with rebamipide. Rebamipide thus inhibited the induction of colitis. Rebamipide significantly reduced concentrations of both interleukin-1alpha and GRO/CINC-1 (IL-8-like substance) and cell infiltrates in colonic wall, in parallel with decreased activity of myeloperoxidase. It also reduced expression of IL-1 mRNA but did not influence expression of GRO/CINC-1 mRNA. The attenuation of colonic indices of colitis by rebamipide in this rat model suggests that this drug might have beneficial effects in the treatment of human ulcerative colitis. These effects of rebamipide are attributable to its inhibition of inflammatory cytokine-mediated granulocyte (neutrophil) infiltration into the colon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.